| Target Professions: | DO, MD, Pharmacist |
| Target Specialties: | Oncology, Gastroenterology, Pathology |
| Credits Available: | 4.75 AMA PRA Category 1 Credit™/ MOC Points |
This curriculum is designed to equip multidisciplinary clinicians with the up-to-date knowledge and skills needed to accurately identify, interpret, and apply dMMR/MSI-H biomarker testing in the management of early and locally advanced colorectal cancer. Through an evidence-based exploration of tumor biology, testing methodologies, guideline updates, and emerging immunotherapy strategies, learners will gain the competence to integrate universal testing into routine workflows and make informed, individualized treatment decisions—particularly as immunotherapy reshapes neoadjuvant and adjuvant paradigms. By completing this curriculum, participants will be better prepared to optimize patient selection, coordinate multidisciplinary care, and improve outcomes for patients with early-stage dMMR/MSI-H colorectal cancer.
Please answer the following questions to assess your knowledge on identifying, testing, and managing patients with dMMR/MSI-H CRC using a collaborative, multidisciplinary approach.
This module covers the biology of the MMR system, the rationale for universal testing in all CRC patients, and the prognostic significance of dMMR/MSI-H status in early-stage disease.
This module reviews NCCN guidelines for universal testing, compares IHC, PCR, and NGS methodologies, and outlines reflex testing strategies to ensure accurate biomarker identification.
This module explores the paradigm shift of ICIs into curative-intent settings, analyzing neoadjuvant and adjuvant trial data and management strategies for non-responders in early-stage CRC
Please answer the following questions to assess the knowledge you have gained in identifying, testing, and managing dMMR/MSI-H CRC using a collaborative approach to improve patient outcomes.
This Live Group Discussion will focus on a case of a 35-year-old male who presented with rectal bleeding and altered bowel habits. We will also address any questions you may have regarding the baseline and final assessments and the self-study modules.
Meet EL, a 62-year-old woman who underwent upfront resection for colon cancer. Determine the implications of postoperative dMMR discovery and select adjuvant therapy based on recent trials (ATOMIC).
Meet JS, a 45-year-old man with dMMR rectal cancer who initiates neoadjuvant immunotherapy but fails to achieve a clinical complete response (cCR), requiring a critical pivot in management strategy.
Considering the information reviewed and discussed during this program, please share the action plan you will implement to improve outcomes for patients with dMMR/MSI-H Colorectal Cancer.
This Live Group Discussion will review a case of a 58-year-old female who underwent an upfront right hemicolectomy for a symptomatic cecal mass. We will also review your submissions on the Patient Case Challenge and Action Plans.
